Drugs / HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED
HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06489015 | Aug 2024 → Apr 2026 | Alzheimer disease | Protgen Ltd | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT05179265 | Mar 2021 → Jul 2022 | — | Protgen Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04701697 | Mar → Sep 2020 | — | The First Hospital of Jilin University | Completed | No outcome recorded |
| Phase 1 | NCT04384523 | Nov 2019 → Mar 2020 | — | Healthgen Biotechnology Corp. | Completed | No outcome recorded |
| Phase 1 | NCT03786289 | Dec 2018 → Jul 2019 | — | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04835480 | Mar 2021 → Jun 2022 overdue | cirrhosis of liver | Healthgen Biotechnology Corp. | Recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06553456 | Aug 2024 → May 2025 | cirrhosis of liver | Protgen Ltd | Completed | No outcome recorded |
| Phase 2/3 | NCT05858853 | May → Sep 2023 | cirrhosis of liver | Protgen Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06355479 | Apr → Nov 2023 | cirrhosis of liver | Healthgen Biotechnology Corp. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07634549 | Jun 2026 → Jul 2027 expected | hypoproteinemia, hypercatabolic | Cheng Qi | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05249374 Comparator | Oct 2021 → May 2022 | — | Protgen Ltd | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068619 ↗ |
| Known as | OsrHSA | “OsrHSA, a recombinant HSA from bioengineered Oryza sativa” PMID 40555465 ↗ Aug 2025 |
| Known as | Recombinant Human Albumin Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04701697 ↗ |
| Known as | recombinant human serum albumin | “Recombinant human serum albumin (rHA)” PMID 40699522 ↗ Jul 2025 |
| Known as | Recombinant human serum albumin/erythropoietin fusion protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03786289 ↗ |
| Known as | rHA | “Recombinant human serum albumin (rHA)” PMID 40699522 ↗ Jul 2025 |
| Known as | rHSA | “This trial adopts random, double-blind, positive control, parallel group design to evaluate the effectiveness and safety of recombinant human serum albumin versus human serum...” NCT06553456 ↗1“This is a randomized, double-blind, position-controlled, parallel group phase II/III clinical study of recombinant human serum albumin (rHSA) in cirrhotic ascites patients.” NCT05858853 ↗ |
| Known as | Rice-derived recombinant human serum albumin | “Rice-derived recombinant human serum albumin (OsrHSA)” NCT07634549 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1” NCT03786289 ↗ |
| Route | Subcutaneous | “Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1” NCT03786289 ↗ |